
|Videos|January 2, 2019
Race/Ethnicity and Clinical Outcomes in Breast Cancer
Advertisement
Transcript:
Joseph A. Sparano, MD: There was a very interesting presentation by Dr. Kathy Albain, one of the co-investigators of the TAILORx trial, that focused on the impact of race and ethnicity on clinical outcomes. And there were several really important conclusions that came from this. First of all, about 8% of the patients who enrolled in the trial were African American, and somewhere in the order of 12% or so were of Hispanic ethnicity. When we looked at the clinical characteristics of the black or Hispanic patients versus nonblack or white patients, and Hispanic versus non-Hispanic populations, the clinical characteristics were largely similar
Advertisement
Related to this article

Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.

The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
2
Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC
3
Galinpepimut-S Improves OS in AML in Second or Later Remission
4
ESMO 2026 Data Highlight ADC Activity in Brain Metastases and TNBC
5




